Asia On The Move: New CFDA Directors, AZ China GM
This article was originally published in PharmAsia News
The China FDA has appointed several key directors and UK drug maker AstraZeneca has quietly changed its China head to a locally grown executive. Personnel changes also take place in major domestic maker Hisun, the China State Administration for Industry and Commerce (SAIC), Acucela and AdvaMed.
You may also be interested in...
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
As the US responds to calls to waive intellectual property rights related to COVID-19 vaccines, China is already moving ahead with some of its own mRNA candidates.
Amid controversy over vaccines protection efficacy, China overhauls its disease control system with a brand-new agency to oversee disease control and prevention measures.